Drug Trial Radar · NCT07104617
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)
Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Oct 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
TY-302Drug
Take the specified dose (75mg or 100mg) orally once a day. Take it on an empty stomach in the morning with about 200 mL of warm water.
AbiraptorDrug
Take orally, 1000mg each time, once a day. Take it on an empty stomach in the morning with warm water, or take it orally at least two hours after fasting.
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Escalation stage) Dose Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
- Maximum tolerated dose(MTD)Time frame: Within 28 days of the first dose
- (Escalation stage) Recommended Phase 2 Dose(RP2D)Time frame: Within 28 days of the last patient dosed in escalation stage
- Adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
- (Expansion stage) Progression-free survival (rPFS)Time frame: Up to approximately 21 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.